CRlSPR/Cas9 screening revealed BlRC6-AS1/BlRC6 mediates abiraterone resistance via NHEJ pathway-dependent A20 degradation in prostate cancer
Li, L.; An, X.-N.; Ruan, Y.; Yang, R.; Li, P.; Wu, X.-Y.; Huang, X.-C.; gao, p.; Dong, X.-M.
Show abstract
Abiraterone acetate serves as the first-line therapeutic agent for prostate cancer (PCa) treatment. However, drug resistance frequently emerges. Employing a genome-wide CRISPR/Cas9 library screening strategy, we identified 523 long non-coding RNAs (lncRNAs) and 2183 protein-coding genes associated with abiraterone resistance. Notably, a pair of sense-antisense genes, BIRC6-AS1/BIRC6, was demonstrated to be a pivotal driver for abiraterone resistance. BIRC6-AS1 depletion led to a reduction in both the mRNA and protein levels of BIRC6. Moreover, depletion of either BIRC6-AS1 or BIRC6 enhanced the chemosensitivity of PCa cells to abiraterone both in vitro and in vivo settings. Further investigation revealed that BIRC6-AS1 stabilized the mRNA of BIRC6 through interaction with ILF2. Diminishing either BIRC6-AS1 or BIRC6 predominantly suppressed non-homologous end joining (NHEJ) repair activity, resulting in the disassembly of 53BP1 foci at DNA damage sites and an increased accumulation of DNA damage in PCa cells induced by abiraterone. Mechanistically, BIRC6 interacted with A20 and facilitated the K48-linked ubiquitination and subsequent degradation of A20 at the K337 residue. Additionally, A20 knockdown effectively reversed the abiraterone sensitivity induced by BIRC6-AS1 depletion. Collectively, we conducted a comprehensive screen to identify lncRNAs and protein-coding genes associated with abiraterone resistance and proposed that targeting BIRC6-AS1/BIRC6 axis represents a promising strategy to overcome abiraterone resistance in prostate cancer.
Matching journals
The top 5 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Transcriptional network involving ERG and AR orchestrates Distal-Less Homeobox 1 mediated prostate cancer progression. 96%
- Role of Specialized mSWI/SNF Complexes in Prostate Cancer Lineage Plasticity 95%
- The pan-cancer lncRNA PLANE regulates an alternative splicing program to promote cancer pathogenesis 95%
Similar papers in this journal
- m6A Demethylase FTO Stabilizes LINK-A to Exert Oncogenic Roles via MCM3-Mediated Cell Cycle Progression and HIF-1α Activation 96%
- Reduced NCOR2 expression accelerates androgen deprivation therapy failure in prostate cancer 95%
- A Cancer-Specific Antigen Drives Histone Acetylation by Stabilizing the Acetyltransferases 95%
Similar papers in this journal
- AR coactivators, CBP/p300, are critical mediators of DNA repair in prostate cancer 96%
- Inhibition of the YAP-MMB interaction and targeting NEK2 as potential therapeutic strategies for YAP-driven cancers 95%
- Disassembly of hemidesmosomes promotes tumorigenesis in PTEN-negative prostate cancer by targeting plectin into focal adhesions 95%
Similar papers in this journal
- The CIC-ERF co-deletion underlies fusion independent activation of ETS family member, ETV1, to drive prostate cancer progression 96%
- GCN2 eIF2 kinase promotes prostate cancer by maintaining amino acid homeostasis 95%
- Loss function of tumor suppressor FRMD8 confers resistance to tamoxifen therapy via a dual mechanism 95%
Similar papers in this journal
- The E3 ligase NEDD4L prevents colorectal cancer liver metastasis via degradation of PRMT5 to inhibit the AKT/mTOR signaling pathway 94%
- TSHR-targeting nucleic acid aptamer treats Graves' ophthalmopathy via novel allosteric inhibition 93%
- Chromatin Remodeling in Patient-Derived Colorectal Cancer Models 92%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.